(Q44353708)

2 December 2017

0 references

1 reference

title

Rifampin and pyrazinamide for treatment of latent tuberculosis infection: is it safe? (English)

1 reference

2 December 2017

1 reference

1 reference

1 reference

1 reference

Robert M Jasmer

1

1 reference

2 December 2017

Charles L Daley

series ordinal

2

1 reference

2 December 2017

language of work or name

English

0 references

publication date

1 March 2003

1 reference

American Journal of Respiratory and Critical Care Medicine

2 December 2017

published in

1 reference

2 December 2017

volume

167

1 reference

2 December 2017

issue

6

1 reference

2 December 2017

page(s)

809-810

1 reference

Hepatotoxicity from rifampin plus pyrazinamide: lessons for policymakers and messages for care providers

2 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

Twice weekly tuberculosis preventive therapy in HIV infection in Zambia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

Safety of 2 months of rifampin and pyrazinamide for treatment of latent tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

Acceptability of short-course rifampin and pyrazinamide treatment of latent tuberculosis infection among jail inmates

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

Pyrazinamide and rifampin vs isoniazid for the treatment of latent tuberculosis: improved completion rates but more hepatotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2301002

21 January 2018

Identifiers

DOI

10.1164/RCCM.2301002

1 reference

release_ork5iczdjjb7hfpr7gpzkeb6t4

2 December 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ork5iczdjjb7hfpr7gpzkeb6t4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference